Jefferies says Roche-Zealand obesity study won’t change outlook
Jefferies said the latest petrelintide obesity results are unlikely to alter investors’ views, citing a 9.2% weight-loss rate in obese patients with type 2 diabetes and effects broadly as expected.
Story updates
11:59:27 AM UTC
SquawkNews
The latest study results from an obesity drug candidate that Roche Holding and Zealand Pharma are jointly developing seem unlikely to alter investors' views on the product, Jefferies analysts say in a research note. The drug, petrelintide, showed a modest effect in reducing blood-sugar levels and t…